
    
      Other outcome measures included serum levels of LH, PSA, as well as non-clinical assessments,
      eg, WHO Performance Status, pain level assessment, and quality of life questionnaires. Safety
      was evaluated via adverse events, vital signs, clinical laboratory outcomes, physical
      examinations, and ECGs. Local tolerability outcomes were also evaluated.

      An extension period for the study included annual replacement of the implant until the
      implant was approved by the FDA (October 12, 2004). Efficacy and safety were followed during
      the extension period.
    
  